Spinogenix awarded $1M to advance clinical testing of SPG302
Spinogenix has won a nearly $1 million grant from the U.S. Department of Defense (DoD) to move ahead with clinical testing of SPG302, a small molecule candidate for amyotrophic lateral sclerosis (ALS). This is DoD’s Congressionally Directed Medical Research Programs’ second grant to the company, following a…